应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
GILD 吉利德科学
盘前交易 04-26 07:28:27 EDT
65.27
-1.81
-2.70%
盘前
65.31
+0.04
+0.06%
07:28 EDT
最高
67.90
最低
65.09
成交量
1,517万
今开
67.47
昨收
67.08
日振幅
4.19%
总市值
813.90亿
流通市值
812.18亿
总股本
12.47亿
成交额
9.95亿
换手率
1.22%
流通股本
12.44亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Needham:重申Gilead Sciences(GILD.US)持有评级。
智通财经 · 53分钟前
Needham:重申Gilead Sciences(GILD.US)持有评级。
吉利德科学:一季度产品销售总额66亿美元 同比增长5%
证券时报网 · 15:01
吉利德科学:一季度产品销售总额66亿美元 同比增长5%
吉利德科学第一季度产品销售总额66亿美元,同比增长5%
界面 · 14:46
吉利德科学第一季度产品销售总额66亿美元,同比增长5%
吉利德科学一季度营收66.9亿美元,高于预期
金融界 · 08:23
吉利德科学一季度营收66.9亿美元,高于预期
吉利德彻底放弃CD47单抗开发
医药魔方 · 07:54
吉利德彻底放弃CD47单抗开发
吉利德科学公司(Gilead Sciences Inc)公布截至三月份的季度业绩 - 收益摘要
Reuters · 07:08
吉利德科学公司(Gilead Sciences Inc)公布截至三月份的季度业绩 - 收益摘要
吉利德公布季度亏损,收入增长 5
Reuters · 04:02
吉利德公布季度亏损,收入增长 5
BUZZ-前瞻:吉利德科学公司下跌超过 2%,将于收盘后发布财报
Reuters · 02:48
BUZZ-前瞻:吉利德科学公司下跌超过 2%,将于收盘后发布财报
吉利德科学下跌1.37%,报66.16美元/股
金融界 · 04-25 22:01
吉利德科学下跌1.37%,报66.16美元/股
未来一天的看点 - 4月25日星期四
Reuters · 04-25 02:30
未来一天的看点 - 4月25日星期四
美国研究综述-Blackstone、Ellington Financial、Netflix
Reuters · 04-19
美国研究综述-Blackstone、Ellington Financial、Netflix
瑞银:维持Gilead Sciences(GILD.US)评级,由中性调整至中性评级, 目标价由81.00美元调整至75.00美元。
智通财经 · 04-18
瑞银:维持Gilead Sciences(GILD.US)评级,由中性调整至中性评级, 目标价由81.00美元调整至75.00美元。
BUZZ-Nurix Therapeutics 在增发 1.75 亿美元股票后下跌
Reuters · 04-12
BUZZ-Nurix Therapeutics 在增发 1.75 亿美元股票后下跌
吉利德科学上涨1.25%,报68.97美元/股
金融界 · 04-12
吉利德科学上涨1.25%,报68.97美元/股
吉利德科学下跌1.23%,报70.02美元/股
金融界 · 04-05
吉利德科学下跌1.23%,报70.02美元/股
吉利德科学下跌1.21%,报72.0美元/股
金融界 · 04-03
吉利德科学下跌1.21%,报72.0美元/股
吉利德科学(GILD.US)超6亿美元囊获创新肿瘤免疫疗法
智通财经 · 03-29
吉利德科学(GILD.US)超6亿美元囊获创新肿瘤免疫疗法
【医疗健康周报】第12周:创新疫苗和佐剂开发商“华诺泰生物”获得6亿元人民币B轮融资;生物制药公司“CymaBay”以约43亿美元被吉利德并购
钛媒体APP · 03-27
【医疗健康周报】第12周:创新疫苗和佐剂开发商“华诺泰生物”获得6亿元人民币B轮融资;生物制药公司“CymaBay”以约43亿美元被吉利德并购
加载更多
公司概况
公司名称:
吉利德科学
所属市场:
NASDAQ
上市日期:
--
主营业务:
吉利德科学公司于1987年6月22日在特拉华州成立,是一家以研究为基础的生物制药公司,致力于发现,开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病,炎性和纤维化疾病以及肿瘤学。
发行价格:
--
{"stockData":{"symbol":"GILD","market":"US","secType":"STK","nameCN":"吉利德科学","latestPrice":65.27,"timestamp":1714075200000,"preClose":67.08,"halted":0,"volume":15171935,"hourTrading":{"tag":"盘前","latestPrice":65.31,"preClose":65.27,"latestTime":"07:28 EDT","volume":185,"amount":12100.84926,"timestamp":1714130895704},"delay":0,"floatShares":1244337698,"shares":1246969303,"eps":4.5,"marketStatus":"盘前交易","marketStatusCode":1,"change":-1.81,"latestTime":"04-26 07:28:27 EDT","open":67.47,"high":67.9,"low":65.09,"amount":994878245.1966499,"amplitude":0.04189,"askPrice":65.37,"askSize":7,"bidPrice":65.25,"bidSize":5,"shortable":3,"etf":0,"ttmEps":4.5,"exchange":"NASDAQ","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1714138200000},"adr":0,"listingDate":696056400000,"adjPreClose":65.27,"adrRate":0,"dividendRate":0.045963,"preHourTrading":{"tag":"盘前","latestPrice":65.31,"preClose":65.27,"latestTime":"07:28 EDT","volume":185,"amount":12100.84926,"timestamp":1714130895704},"postHourTrading":{"tag":"盘后","latestPrice":65.15,"preClose":65.27,"latestTime":"19:58 EDT","volume":1378786,"amount":90159951.284,"timestamp":1714089501762},"volumeRatio":2.0824068482909697,"optionData":{"bulkOrders":[{"symbol":"GILD","call":false,"expireDate":1715918400000,"strike":"62.0","timestamp":1714055591214,"price":0.4399999976158142,"volume":16828,"amount":740432,"type":"-"},{"symbol":"GILD","call":true,"expireDate":1714708800000,"strike":"69.0","timestamp":1714072339345,"price":0.27000001072883606,"volume":14910,"amount":402570,"type":"+"}]}},"requestUrl":"/m/hq/s/GILD?invite=033TIGER","defaultTab":"news","newsList":[{"id":"2430922234","title":"Needham:重申Gilead Sciences(GILD.US)持有评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2430922234","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430922234?lang=zh_cn&edition=full","pubTime":"2024-04-26 18:36","pubTimestamp":1714127761,"startTime":"0","endTime":"0","summary":"Needham:重申Gilead Sciences(GILD.US)持有评级。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261836048b56d941&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261836048b56d941&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430210781","title":"吉利德科学:一季度产品销售总额66亿美元 同比增长5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430210781","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2430210781?lang=zh_cn&edition=full","pubTime":"2024-04-26 15:01","pubTimestamp":1714114907,"startTime":"0","endTime":"0","summary":"证券时报e公司讯,吉利德科学发布2024年第一季度财务报告,一季度产品销售总额66亿美元,同比增长5%。其中,HIV产品销售额43亿美元,同比增长4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202404263061137045.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202404263061137045.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430177832","title":"吉利德科学第一季度产品销售总额66亿美元,同比增长5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2430177832","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2430177832?lang=zh_cn&edition=full","pubTime":"2024-04-26 14:46","pubTimestamp":1714113978,"startTime":"0","endTime":"0","summary":"吉利德科学当地时间4月25日公布2024年第一季度财报,第一季度产品销售总额同比增长5%,达66亿美元;必妥维销售额同比增长10%,达29亿美元;肿瘤产品销售额同比增长18%,达7.89亿美元;瑞德西韦销售额5.55亿美元,同比下降3%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261446197a55ff18&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404261446197a55ff18&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430826286","title":"吉利德科学一季度营收66.9亿美元,高于预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2430826286","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430826286?lang=zh_cn&edition=full","pubTime":"2024-04-26 08:23","pubTimestamp":1714090982,"startTime":"0","endTime":"0","summary":"吉利德科学一季度每股亏损1.32美元,分析师预期亏损1.52美元。一季度营收66.9亿美元,分析师预期63.4亿美元。一季度Veklury营收5.55亿美元,分析师预期3.778亿美元。预计全年调整后EPS为3.45-3.85美元,公司之前预计6.85%-7.25美元。维持全年产品(产量)预期不变。公司短期内不会涉足任何重大的并购交易。2月销量暂时性地遭受与调整医保相关的网络袭击的干扰,3月份已经恢复正常。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260835328b54c81a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404260835328b54c81a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430261205","title":"吉利德彻底放弃CD47单抗开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2430261205","media":"医药魔方","top":-1,"share":"https://www.laohu8.com/m/news/2430261205?lang=zh_cn&edition=full","pubTime":"2024-04-26 07:54","pubTimestamp":1714089256,"startTime":"0","endTime":"0","summary":"4月22日,吉利德在公布2024Q1财报的同时,更新了管线进展,其将关于CD47单抗magrolimab的6项试验从管线中剔除。今年2月7日,吉利德宣布,终止magrolimab所有血液瘤项目开发,短短10天后,其又宣布magrolimab实体瘤临床试验遭FDA暂停。而此次6项试验从管线中移除意味着吉利德彻底放弃该款药物的开发。以Magrolimab为代表的CD47靶点曾被认为是下一个重磅炸弹诞生地,然而,该靶点药物开发最终还是以失败告终。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042607571787b0f7e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042607571787b0f7e6&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430265090","title":"吉利德科学公司(Gilead Sciences Inc)公布截至三月份的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2430265090","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430265090?lang=zh_cn&edition=full","pubTime":"2024-04-26 07:08","pubTimestamp":1714086524,"startTime":"0","endTime":"0","summary":" * 吉利德科学公司公布了截至 3 月份的季度调整后每股亏损 1.32 美元,低于去年同期的每股亏损 1.37 美元。23 位分析师对该季度的平均预期是每股亏损 1.49 美元。华尔街预期为每股亏损 1.86 美元至 1.14 美元。* 吉利德科学公司公布的本季度每股收益为亏损 3.34 美元。* 该公司一季度亏损 41.7 亿美元。* 吉利德科学公司本季度股价下跌了 8.4%,今年迄今为止下跌了 17.2%。华尔街对吉利德科学公司 12 个月目标价的中位数为 80.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430562022","title":"吉利德公布季度亏损,收入增长 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2430562022","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430562022?lang=zh_cn&edition=full","pubTime":"2024-04-26 04:02","pubTimestamp":1714075379,"startTime":"0","endTime":"0","summary":" Deena Beasley 路透社4月25日 - 吉利德科学公司 周四公布了第一季度亏损报告,该公司因最近收购肝病药物开发商CymaBay Therapeutics而被计提了39亿美元的费用。吉利德公布的调整后季度每股亏损为 1.32 美元,好于分析师预测的每股亏损 1.48 美元。按净额计算,吉利德公司的季度亏损为每股 3.34 美元。吉利德的肿瘤学销售额增长了 18%,达到 7.89 亿美元。他指出,吉利德预计今年将有几个关键项目的试验结果,包括抗癌药物 Trodelvy。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430538712","title":"BUZZ-前瞻:吉利德科学公司下跌超过 2%,将于收盘后发布财报","url":"https://stock-news.laohu8.com/highlight/detail?id=2430538712","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430538712?lang=zh_cn&edition=full","pubTime":"2024-04-26 02:48","pubTimestamp":1714070919,"startTime":"0","endTime":"0","summary":" 4月25日 - ** 吉利德科学公司 的股价在周四下午的交易中下跌了2.6%,该公司将在收盘后公布季度业绩。** 根据伦敦证券交易所集团的数据,吉利德预计其营业收入将从一年前的63.5亿美元降至63.4亿美元,每股亏损1.49美元,而去年同期每股盈利1.37美元。** 根据LSEG的数据,该公司在过去8个报告期中,有6个报告期的盈利超过了分析师的预期。** 包括本交易日的走势在内,吉利德今年迄今下跌了19%,而同期标准普尔500指数 上涨了6%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2430890082","title":"吉利德科学下跌1.37%,报66.16美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430890082","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430890082?lang=zh_cn&edition=full","pubTime":"2024-04-25 22:01","pubTimestamp":1714053687,"startTime":"0","endTime":"0","summary":"4月25日,吉利德科学(GILD)盘中下跌1.37%,截至22:01,报66.16美元/股,成交6962.42万美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。大事提醒:4月25日,吉利德科学(美东)盘后披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/25220140414670.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430462500","title":"未来一天的看点 - 4月25日星期四","url":"https://stock-news.laohu8.com/highlight/detail?id=2430462500","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2430462500?lang=zh_cn&edition=full","pubTime":"2024-04-25 02:30","pubTimestamp":1713983434,"startTime":"0","endTime":"0","summary":"美国劳工部的每周失业救济申请数据可能会显示,在截至4月20日的一周内,各州首次申请失业救济的人数增加了3000人,经季节性因素调整后为215000人。与此同时,首次领取失业救济金的人数可能从截至4月13日当周的181.2万人降至180.5万人。美国航空公司将公布第一季度财报。由于主要市场需求低迷,陶氏预计将公布第一季度收入下降的报告。烟草巨头 Altria 将公布第一季度业绩。受客户转向广告流媒体的帮助,Roku 第一季度收入预计将增长 14.52%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428668911","title":"美国研究综述-Blackstone、Ellington Financial、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2428668911","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2428668911?lang=zh_cn&edition=full","pubTime":"2024-04-19 15:24","pubTimestamp":1713511479,"startTime":"0","endTime":"0","summary":" 路透社4月19日 - 华尔街证券分析师周五调整了对几家美国上市公司的评级和目标价,其中包括黑石集团、艾灵顿金融公司和 Netflix。要闻 * 黑石集团 :Piper Sandler 将目标价从 146 美元下调至 143 美元 * Ellington Financial Inc :Jonestrading 给予其 \"持有 \"评级 * Netflix Inc :Pivotal Research将目标价从765美元上调至800美元 以下是路透社周五报道的美国公司研究行动摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2428567780","title":"瑞银:维持Gilead Sciences(GILD.US)评级,由中性调整至中性评级, 目标价由81.00美元调整至75.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428567780","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2428567780?lang=zh_cn&edition=full","pubTime":"2024-04-18 19:36","pubTimestamp":1713440183,"startTime":"0","endTime":"0","summary":"瑞银:维持Gilead Sciences(GILD.US)评级,由中性调整至中性评级, 目标价由81.00美元调整至75.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181936268b35e18e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404181936268b35e18e&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426783006","title":"BUZZ-Nurix Therapeutics 在增发 1.75 亿美元股票后下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2426783006","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2426783006?lang=zh_cn&edition=full","pubTime":"2024-04-12 19:37","pubTimestamp":1712921821,"startTime":"0","endTime":"0","summary":" 4月12日 - ** Nurix Therapeutics Inc 的 股价在隔夜后续定价后盘前下跌 5.3%,报 16.30 美元。** 生物制药公司周四晚些时候宣布, ~1170万股,包括150万份预筹资认股权证,发行价为15美元,筹资总额为1.75亿美元。** Nurix本月早些时候宣布延长与吉利德科学公司 的合作。2023 年第四季度,该公司与辉瑞 达成新的合作。** Nurix 拥有约 4 920 万股已发行股票,市值约 8.46 亿美元** 截至本周四,公司股价已累计上涨 67** 摩根大通、Piper Sandler 和 Stifel 担任股票发行的账簿管理人","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426296458","title":"吉利德科学上涨1.25%,报68.97美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2426296458","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2426296458?lang=zh_cn&edition=full","pubTime":"2024-04-12 02:08","pubTimestamp":1712858894,"startTime":"0","endTime":"0","summary":"4月12日,吉利德科学(GILD)盘中上涨1.25%,截至02:08,报68.97美元/股,成交2.17亿美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。大事提醒:4月25日,吉利德科学将于(美东)盘后披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/12020840206400.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2425341542","title":"吉利德科学下跌1.23%,报70.02美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2425341542","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2425341542?lang=zh_cn&edition=full","pubTime":"2024-04-05 02:35","pubTimestamp":1712255745,"startTime":"0","endTime":"0","summary":"4月5日,吉利德科学(GILD)盘中下跌1.23%,截至02:35,报70.02美元/股,成交2.25亿美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。大事提醒:4月25日,吉利德科学将披露2024财年一季报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/05023540127771.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2424209790","title":"吉利德科学下跌1.21%,报72.0美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2424209790","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2424209790?lang=zh_cn&edition=full","pubTime":"2024-04-03 01:35","pubTimestamp":1712079326,"startTime":"0","endTime":"0","summary":"4月3日,吉利德科学(GILD)盘中下跌1.21%,截至01:35,报72.0美元/股,成交1.8亿美元。财务数据显示,截至2023年12月31日,吉利德科学收入总额271.16亿美元,同比减少0.6%;归母净利润56.65亿美元,同比增长23.37%。大事提醒:4月25日,吉利德科学将披露2024财年一季报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/04/03013540103960.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2423171813","title":"吉利德科学(GILD.US)超6亿美元囊获创新肿瘤免疫疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2423171813","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2423171813?lang=zh_cn&edition=full","pubTime":"2024-03-29 07:50","pubTimestamp":1711669808,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,3月29日,吉利德科学和Xilio Therapeutics宣布达成一项总额可能超过6亿美元的独家许可协议,两家公司将共同开发和商业化Xilio的肿瘤激活白介素12蛋白XTX301,该在研药物目前处于临床1期阶段。XTX301目前正在治疗晚期实体瘤患者的1期剂量递增试验中接受评估。在Xilio交付XTX301的指定临床数据后,吉利德可以选择获得XTX301的开发和商业化权利,并支付7500万美元的费用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1096048.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422529449","title":"【医疗健康周报】第12周:创新疫苗和佐剂开发商“华诺泰生物”获得6亿元人民币B轮融资;生物制药公司“CymaBay”以约43亿美元被吉利德并购","url":"https://stock-news.laohu8.com/highlight/detail?id=2422529449","media":"钛媒体APP","top":-1,"share":"https://www.laohu8.com/m/news/2422529449?lang=zh_cn&edition=full","pubTime":"2024-03-27 16:37","pubTimestamp":1711528648,"startTime":"0","endTime":"0","summary":"国内投融资方面,医药领域,创新疫苗和佐剂开发商“华诺泰生物”获得6亿元人民币B轮融资,核医学CRDMO“米度生物”融资近4亿元人民币。国外投融资方面,医药领域,生物制药公司“CymaBay”以约43亿美元被吉利德并购;生物技术领域,生物技术公司“Capstan Therapeutics”在B系列融资中筹集了1.75亿美元。医药“华诺泰生物”获得6亿人民币B轮融资日前,“华诺泰生物”正式宣布完成总额6亿元B轮融资。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271642038b68fa12&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403271642038b68fa12&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gilead.com","stockEarnings":[{"period":"1week","weight":-0.0135},{"period":"1month","weight":-0.0986},{"period":"3month","weight":-0.1792},{"period":"6month","weight":-0.1481},{"period":"1year","weight":-0.2206},{"period":"ytd","weight":-0.1943}],"compareEarnings":[{"period":"1week","weight":0.0079},{"period":"1month","weight":-0.0295},{"period":"3month","weight":0.033},{"period":"6month","weight":0.226},{"period":"1year","weight":0.2452},{"period":"ytd","weight":0.0593}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"吉利德科学公司于1987年6月22日在特拉华州成立,是一家以研究为基础的生物制药公司,致力于发现,开发和商业化未满足医疗需求的创新药物。该公司的主要重点领域包括病毒性疾病,炎性和纤维化疾病以及肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.5625,"avgChangeRate":0.041198},{"month":2,"riseRate":0.393939,"avgChangeRate":0.002047},{"month":3,"riseRate":0.545455,"avgChangeRate":-0.009403},{"month":4,"riseRate":0.545455,"avgChangeRate":0.013855},{"month":5,"riseRate":0.5625,"avgChangeRate":0.021083},{"month":6,"riseRate":0.625,"avgChangeRate":0.024943},{"month":7,"riseRate":0.53125,"avgChangeRate":0.013302},{"month":8,"riseRate":0.53125,"avgChangeRate":0.033833},{"month":9,"riseRate":0.5625,"avgChangeRate":0.031735},{"month":10,"riseRate":0.5,"avgChangeRate":-0.00096},{"month":11,"riseRate":0.625,"avgChangeRate":0.039318},{"month":12,"riseRate":0.40625,"avgChangeRate":0.011587}],"exchange":"NASDAQ","name":"吉利德科学","nameEN":"Gilead Sciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"吉利德科学,GILD,吉利德科学股票,吉利德科学股票老虎,吉利德科学股票老虎国际,吉利德科学行情,吉利德科学股票行情,吉利德科学股价,吉利德科学股市,吉利德科学股票价格,吉利德科学股票交易,吉利德科学股票购买,吉利德科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"吉利德科学(GILD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供吉利德科学(GILD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}